Movers and SHAKERS
Lineage Cell Therapeutics (LCTX)
Transformation on Track, Reiterating Outperform Rating
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.
Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
License agreement on OPC1 delivery system to treat spinal cord injury. Lineage entered into an exclusive license agreement with Neurgain Technologies, a private company focused on the treatment of spinal cord trauma-induced neuropathic pain. Lineage made immaterial upfront payments and is obligated to pay milestone payments; the terms of the deal were not disclosed. Lineage and Neurgain will evaluate Neurgain’s novel Parenchymal Delivery Injection (PDI) system for the administration of cells to the spinal cord without stopping the patient’s respiration that is expected to reduce the complexity, risk, and variability of the procedure. PDI system is expected to be ready to use for OPC1 clinical studies by YE 2021.
Progress on OPC1 program. Lineage made significant progress in the manufacturing of OPC1 including a 10-20x increase in production scale, reduced impurities, and ready to inject formulation. The company is having discussions with the FDA to determine the path forward for this program ...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.